Vanguard Group Inc Assembly Biosciences, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.65 - $1.25 $64,409 - $123,865	99,092 Added 4.42%	2,339,088 $1.92 Million
Q3 2023 Nov 14, 2023	SELL	$0.87 - $1.13 $29,376 - $38,155	-33,766 Reduced 1.49%	2,239,996 $1.99 Million
Q1 2023 May 15, 2023	BUY	$0.8 - $1.74 $64,640 - $140,592	80,800 Added 3.68%	2,273,762 $1.91 Million
Q4 2022 Feb 10, 2023	SELL	$1.09 - $1.52 $10,714 - $14,941	-9,830 Reduced 0.45%	2,192,962 $2.85 Million
Q3 2022 Nov 14, 2022	SELL	$1.7 - $2.34 $89,474 - $123,158	-52,632 Reduced 2.33%	2,202,792 $3.61 Million

Q2 2022 Aug 12, 2022	BUY	$1.35 - $2.29 $846,593 - $1.44 Million	627,106 Added 38.51%	2,255,424 $4.74 Million
Q1 2022 May 13, 2022	SELL	$1.46 - $2.45 $842,033 - $1.41 Million	-576,735 Reduced 26.16%	1,628,318 $3.35 Million
Q4 2021 Feb 14, 2022	BUY	$2.13 - $3.46 $641,811 - $1.04 Million	301,320 Added 15.83%	2,205,053 $5.14 Million
Q3 2021 Nov 12, 2021	BUY	$3.14 - $3.9 $63,079 - $78,347	20,089 Added 1.07%	1,903,733 $6.63 Million
Q2 2021 Aug 13, 2021	BUY	$3.8 - $4.56 $7.16 Million - $8.59 Million	1,883,644 New	1,883,644 $7.31 Million

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $665M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.